75
Participants
Start Date
February 25, 2021
Primary Completion Date
January 16, 2025
Study Completion Date
January 16, 2025
JNJ-64264681
JNJ-64264681 capsules will be administered orally.
JNJ-67856633
JNJ-67856633 capsules or tablets will be administered orally.
Scientia Clinical Research, Randwick
Peter MacCallum Cancer Centre, Melbourne
Seoul National University Hospital, Seoul
Monash Medical Centre, Clayton
CHU UCL Namur - Site Godinne, Yvoir
Linear Clinical Research Ltd, Nedlands
AZ St.-Jan Brugge-Oostende AV, Bruges
Universitair Ziekenhuis Gent - UZ GENT, Ghent
Stony Brook University Medical Center, Stony Brook
Hosp Univ Fund Jimenez Diaz, Madrid
CHU Bretonneau, Tours
Chu Hotel Dieu, Nantes
Sheba Medical Center, Ramat Gan
CHRU de Lille Hopital Claude Huriez, Lille
Centre hospitalier Lyon-Sud, Pierre-Bénite
Tel Aviv Sourasky MC, Tel Aviv
Hadassah Medical Center, Jerusalem
Arensia Exploratory Medicine, Tbilisi
Arensia Exploratory Medicine, Chisinau
Academic Medical Center, Amsterdam
Uniwersyteckie Centrum Kliniczne, Gdansk
Pratia Onkologia Katowice, Katowice
Pratia MCM Krakow, Krakow
Centrum Medyczne Pratia Poznan, Skorzewo
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hosp Univ Vall D Hebron, Barcelona
Medical Center of Limited Liability Company Arensia Exploratory Medicine, Kyiv
Janssen Research & Development, LLC
INDUSTRY